The novel vaccine delivery devices market is projected to grow at an annualized rate of ~20%:By RootsAnalysis:
Roots Analysis has done a detailed study on “NovelVaccine Delivery Devices Market, 2019-2030” covering key aspects of the industry’s evolution andidentifying potential future growth opportunities.
To order this 500+page report, which features 90+ figures and 160+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/vaccine-delivery-devices/280.html
Key Market Insights
§ Over 130 novelvaccine delivery devices, including marketed / under development products, arebeing investigated for the delivery of both liquid and solid formulations forvaccines
§ The market landscapeis fragmented, featuring both new entrants (small companies) and establishedplayers (mid-large sized enterprises); the US is currently considered to be thehub for vaccine delivery focused firms
§ A myriad of invasiveand non-invasive delivery devices based on different routes of administrationsare under evaluation; majority of them are in clinical stages of development
§ In order to achievean edge over competing players, delivery device developers in this market areincreasingly focusing on the integration of advanced features in theirrespective products / offerings
§ An evaluation of 490+marketed and pipeline products revealed that several vaccine candidates arelikely to be considered for delivery via novel vaccine delivery device in thenear future
§ An increasinginterest in the field is also reflected in the partnership activity, dealsinked in the recent past were focused on a diverse range of devices, andinvolved both international and indigenous stakeholders
§ The benefits of thenovel vaccine deliver devices presently outweigh the challenges related totheir development and sales; the growing optimism in this domain is evident inthe opinions of industry veterans
§ The futureopportunity for novel vaccine delivery devices is expected to be distributedacross various product types, routes of administration and key geographicalregions
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/vaccine-delivery-devices/280.html or email sales@rootsanalysis.com
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVESUMMARY
3. INTRODUCTION
3.1. An Overview ofVaccines
3.1.1. Classification of Vaccines
3.1.1.1. Live, Attenuated Vaccines
3.1.1.2. Inactivated Vaccines
3.1.1.3. Subunit Vaccines
3.1.1.4. Toxoid Vaccines
3.1.1.5. DNA Vaccines
3.1.2. Key Components ofVaccine Formulations
3.1.3. Production of Vaccines inDifferent Expression Systems
3.1.3.1. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts(CEFs)
3.1.3.2. Mammalian Expression Systems
3.1.3.3. Avian Expression Systems
3.1.3.4. Plant Expression Systems
3.1.3.5. Bacterial Expression Systems
3.1.3.6. Yeast Expression Systems
3.1.3.7. Insect Expression System
3.1.4. Routes ofAdministration for Vaccines
3.1.4.1. Intradermal Route
3.1.4.2. Subcutaneous Route
3.1.4.3. Intramuscular Route
3.1.4.4. Oral Route
3.1.4.5. Intranasal Route
3.1.4.6. Inhalation
3.1.5. Key ChallengesAssociated with Vaccine Delivery
3.1.6. Novel Approaches for VaccineDelivery Devices
3.1.6.1. Autoinjectors
3.1.6.2. Biodegradable Implants
3.1.6.3. Buccal / Sublingual Vaccine Delivery Systems
3.1.6.4. Electroporation
3.1.6.5. Inhalation / Pulmonary Vaccine Delivery Systems
3.1.6.6. Jet Injectors
3.1.6.7. Microinjection System
3.1.6.8. Novel Oral Vaccine Formulations
3.1.7. Future Perspectives
4. MARKETLANDSCAPE
4.1. Chapter Overview
4.2. Marketed Vaccines Landscape
4.3. Clinical-Stage VaccinesLandscape
4.4. Novel VaccineDelivery Devices: Overall Market Landscape
4.4.1. Analysis by Type of Device
4.4.2. Analysis by Route ofAdministration
4.4.3. Analysis by Drug DeliveryMechanism
4.4.4. Analysis by Nature of VaccineAdministration
4.4.5. Analysis by Speed of VaccineAdministration
4.4.6. Analysis by Self-AdministrationPotential
4.4.7. Analysis by Availability ofAudio / Visual Feedback
4.4.8. Analysis by Device Usability
4.4.9. Analysis by Type of Needle
4.4.10. Analysis by Stage of Development
4.5. Novel VaccineDelivery Device Developers: Overall Market Landscape
4.5.1. Analysis by Type of Developer
4.5.2. Analysis by Year ofEstablishment
4.5.3. Analysis by Company Size
4.5.4. Analysis by GeographicalLocation
5. DEVICECOMPETITIVENESS ANALYSIS
5.1. Chapter overview
5.2. Assumptions and Methodology
5.2.1. Device Competitiveness Analysis:Competitive Landscape
6. TECHNOLOGYEFFECTIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Vaccine Delivery Devices: TechnologyEffectiveness Analysis
6.4.1. Devices for Marketed Vaccines
6.4.1.1. Analysis by Type of Active Ingredient
6.4.1.2. Analysis by Dosage Form
6.4.1.3. Analysis by Route of Administration
6.4.1.4. Analysis by Target Disease Indication
6.4.1.5. Analysis by Target Patient Population
6.4.2. Devices for Clinical-StageVaccines
6.4.2.1. Analysis by Type of Active Ingredient
6.4.2.2. Analysis by Dosage Form
6.4.2.3. Analysis by Route of Administration
6.4.2.4. Analysis by Target Disease Indication
6.4.2.5. Analysis by Target Patient Population
7. NOVELVACCINE DELIVERY DEVICES: LIKELY VACCINE CANDIDATES
7.1. Chapter Overview
7.2. Methodology and Key Parameters
7.3. MarketedVaccines
7.3.1. Electroporation-based NeedleFree Injection Systems: Likely Vaccine
7.3.1.1. Most Likely Candidates for Delivery via Electroporation-based NeedleFree Injection Systems
7.3.1.2. Likely Candidates for Delivery via Electroporation-based Needle FreeInjection SystemsSystems
7.3.1.3. Less Likely Candidates for Delivery via Electroporation-based NeedleFree Injection Systems
7.3.1.4. Least Likely Candidates for Delivery via Electroporation-based NeedleFree Injection Systems
7.3.2. Jet Injectors:Likely Vaccine Candidates
7.3.2.1. Most Likely Candidates for Delivery via Jet Injectors
7.3.2.2. Likely Candidates for Delivery via Jet Injectors
7.3.2.3. Less Likely Candidates for Delivery via Jet Injectors
7.3.2.4. Least Likely Candidates for Delivery via Jet Injector
7.3.3. MicroneedlePatches: Likely Vaccine Candidates
7.3.3.1. Most Likely Candidates for Delivery via Microneedle Patches
7.3.3.2. Less Likely Candidates for Delivery via Microneedle Patches
7.3.3.3. Least Likely Candidates for Delivery via Microneedle Patches
7.3.4. Nasal deliverySystems: Likely Vaccine Candidates
7.3.4.1. Most Likely Candidates for Delivery via Nasal Delivery Systems
7.3.4.2. Likely Candidates for Delivery via Nasal Delivery Systems
7.3.4.3. Less Likely Candidates for Delivery via Nasal Delivery Systems
7.3.4.4. Least Likely Candidates for Delivery via Nasal Delivery Systems
7.3.5. Oral DeliverySystems for Liquid Formulations: Likely Vaccine Candidates
7.3.5.1. Most Likely Candidates for Delivery via Oral Delivery Systems forLiquid Formulations
7.3.5.2. Likely Candidates for Delivery via Oral Delivery Systems for LiquidFormulations
7.3.5.3. Less Likely Candidates for Delivery via Oral Delivery Systems forLiquid Formulations
7.3.5.4. Least Likely Candidates for Delivery via Oral Delivery Systems forLiquid Formulations
7.3.6. Oral Delivery Systems for SolidFormulations: Likely Vaccine Candidates
7.3.6.1. Most Likely Candidates for Delivery via Oral Delivery Systems forSolid Formulations
7.3.6.2. Likely Candidates for Delivery via Oral Delivery Systems for SolidFormulations
7.3.6.3. Less Likely Candidates for Delivery via Oral Delivery Systems forSolid Formulations
7.3.6.4. Least Likely Candidates for Delivery via Oral Delivery Systems forSolid Formulations
7.3.7. PrefilledSyringes: Likely Vaccine Candidates
7.3.7.1. Most Likely Candidates for Delivery via Prefilled Syringes
7.3.7.2. Likely Candidates for Delivery via Prefilled Syringes
7.3.7.3. Less Likely Candidates for Delivery via Prefilled Syringes
7.3.7.4. Least Likely Candidates for Delivery via Prefilled Syringes
7.4. Clinical-StageVaccines
7.4.1. Electroporation-based NeedleFree Injection Systems: Likely Vaccine Candidates
7.4.1.1. Most Likely Candidates for Delivery via Electroporation-based NeedleFree Injection Systems
7.4.1.2. Likely Candidates for Delivery via Electroporation-based Needle FreeInjection Systems
7.4.1.3. Less Likely Candidates for Delivery via Electroporation-based NeedleFree Injection Systems
7.4.1.4. Least Likely Candidates for Delivery via Electroporation-based NeedleFree Injection Systems
7.4.2. Jet Injectors:Likely Vaccine Candidates
7.4.2.1. Most Likely Candidates for Delivery via Jet Injectors
7.4.2.2. Likely Candidates for Delivery via Jet Injectors
7.4.2.3. Less Likely Candidates for Delivery via Jet Injectors
7.4.2.4. Least Likely Candidates for Delivery via Jet Injectors
7.4.3. MicroneedlePatches: Likely Vaccine Candidates
7.4.3.1. Most Likely Candidates for Delivery via Microneedle Patches
7.4.3.2. Likely Candidates for Delivery via Microneedle Patches
7.4.3.3. Less Likely Candidates for Delivery via Microneedle Patches
7.4.3.4. Least Likely Candidates for Delivery via Microneedle Patches
7.4.4. Nasal DeliverySystems: Likely Vaccine Candidates
7.4.4.1. Most Likely Candidates for Delivery via Nasal Delivery Systems
7.4.4.2. Likely Candidates for Delivery via Nasal Delivery Systems
7.4.4.3. Less Likely Candidates for Delivery via Nasal Delivery Systems
7.4.4.4. Least Likely Candidates for Delivery via Nasal Delivery Systems
7.4.5. Oral DeliverySystems for Liquid Formulations: Likely Vaccine Candidates
7.4.5.1. Most Likely Candidates for Delivery via Oral Delivery Systems forLiquid Formulations
7.4.5.2. Likely Candidates for Delivery via Oral Delivery Systems for LiquidFormulations
7.4.5.3. Less Likely Candidates for Delivery via Oral Delivery Systems forLiquid Formulations
7.4.5.4. Least Likely Candidates for Delivery via Oral Delivery Systems forLiquid Formulations
7.4.6. Oral DeliverySystems for Solid Formulations: Likely Vaccine Candidates
7.4.6.1. Most Likely Candidates for Delivery via Oral Delivery Systems forSolid Formulations
7.4.6.2. Likely Candidates for Delivery via Oral Delivery Systems for SolidFormulations
7.4.6.3. Less Likely Candidates for Delivery via Oral Delivery Systems forSolid Formulations
7.4.6.4. Least Likely Candidates for Delivery via Oral Delivery Systems forSolid Formulations
7.4.7. PrefilledSyringes: Likely Vaccine Candidates
7.4.7.1. Most Likely Candidates for Delivery via Prefilled Syringes
7.4.7.2. Likely Candidates for Delivery via Prefilled Syringes
7.4.7.3. Less Likely Candidates for Delivery via Prefilled Syringes
7.4.7.4. Least Likely Candidates for Delivery via Prefilled Syringes
8. COMPANYPROFILES
8.1. Company Overview
8.2. 3M
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Product Portfolio
8.2.3.1. 3M™ Hollow Microstructured Transdermal System
8.2.3.2. 3M™ Solid Microneedle
8.2.4. Recent Collaborations
8.2.5. Future Outlook
8.3. Becton Dickinson
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Product Portfolio
8.3.3.1. BD Intevia™ Handheld Autoinjector
8.3.3.2. BD Accuspray™ Nasal Spray System
8.3.4. Future Outlook
8.4. Consort Medical
8.4.1. Company overview
8.4.2. Financial Information
8.4.3. Technology Overview
8.4.4. Product Portfolio
8.4.4.1. Autoinjectors
8.4.4.1.1. Syrina
8.4.4.1.2. OTS Autoinjector
8.4.4.2. Nasal Delivery System
8.4.5. Recent Collaborations
8.4.6. Future Outlook
8.5. D'AntonioConsultants International
8.5.1. Company Overview
8.5.2. Product Portfolio
8.5.2.1. LectraJet® High Speed Jet Injection System
8.5.2.2. LectraJet® M3 RA Needle-Free Injection System
8.5.2.3. LectraJet® M4 RA Needle-Free Injection System
8.5.2.4. Multi-Channel Jet Injector
8.6. Enesi Pharma
8.6.1. Company Overview
8.6.2. Product Portfolio
8.6.2.1. Enesi ImplaVax®
8.6.3. Recent Collaborations
8.6.4. Future Outlook
8.7. Ichor MedicalSystems
8.7.1. Company Overview
8.7.2. Product Portfolio
8.7.2.1. TriGrid® Delivery System
8.7.3. Recent Collaborations
8.7.4. Future Outlook
8.8. Iconovo
8.8.1. Company Overview
8.8.2. Financial Information
8.8.3. Product Portfolio
8.8.3.1. ICOres
8.8.3.2. ICOone
8.8.3.3. ICocap
8.8.3.4. ICopre
8.8.4. Recent Collaborations
8.8.5. Future Outlook
8.9. InovioPharmaceuticals
8.9.1. Company Overview
8.9.2. Financial Information
8.9.3. Product Portfolio
8.9.3.1. ZetaJet®
8.9.3.2. Biojector® 2000
8.9.3.3. CELLECTRA® Electroporation Delivery Device
8.9.4. Recent Collaborations
8.9.5. Future Outlook
8.10. PharmaJet
8.10.1. Company Profile
8.10.2. Product Portfolio
8.10.2.1. PharmaJet Stratis® Needle-Free Injector
8.10.2.2. PharmaJet Tropis® Intradermal Injection
8.10.3. Recent Collaborations
8.10.4. Future Outlook
8.11. Union Medico
8.11.1. Company Overview
8.11.2. Product Portfolio
8.11.2.1. 45˚ Autoinjector
8.11.2.1.1. 45 ˚/ S Autoinjector
8.11.2.1.2. 45 ˚/ M Autoinjector
8.11.2.1.3. 45 ˚/ R Autoinjector
8.11.2.2. 90˚Autoinjector
8.11.2.2.1. 90 ˚ / S Autoinjector
8.11.2.2.2. 90 ˚ / M Autoinjector
8.11.2.2.3. 90 ˚ / XL Autoinjector
8.11.2.2.4. SuperGrip Autoinjector
8.11.2.2.5. Exclusive Autoinjector
8.11.3. Recent Development and FutureOutlook
9. PARTNERSHIPSAND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Novel Vaccine Delivery Devices:Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Type of Device
9.3.4. Analysis by Type of Partnershipand Type of Device
9.3.5. Analysis by Type of Vaccine andType of Device
9.3.6. Analysis by Type of ActiveIngredient
9.3.7. Analysis by Target DiseaseIndication
9.3.8. Popular Vaccine DeliveryDevices: Analysis by Number of Partnerships
9.3.9. Most Active Industry Players:Analysis by Number of Partnerships
9.3.10. Intercontinental and Intracontinental Agreements
10. SWOTANALYSIS
10.1. Chapter Overview
10.2. Strengths
10.2.1. Minimally Invasive / Non-InvasiveVaccine Delivery
10.2.2. Ease of Use
10.2.3. Elimination of Cold-Chain Storage
10.2.4. Economic Advantages
10.2.5. Elimination of Medication Errors
10.3. Weaknesses
10.3.1. Manufacturing Complexities
10.3.2. Cost Concerns
10.3.3. Product Stability Concerns
10.4. Opportunities
10.4.1. Growing Pipeline of Vaccines
10.4.2. Increase in Self-InjectingPatient Population
10.4.3. Growing Incidence of InfectiousDiseases
10.4.4. Innovation in Design andTechnical Advancements
10.4.5. Geographic Expansions
10.5. Threats
10.5.1. Competition from ConventionalDelivery Systems
10.5.2. Strict Regulatory Framework
10.6. Concluding Remarks
11. MARKETSIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and KeyAssumptions
11.3. Global Novel Vaccine DeliveryDevice Market, 2019-2030
11.3.1. Global Novel Vaccine DeliveryDevice Market, 2019-2030 (By Value)
11.3.1.1. Global Novel Vaccine Delivery Devices Market: Distribution by Type ofDevice, 2019-2030 (By Value)
11.3.1.2. Global Novel Vaccine Delivery Device Market: Distribution by Route ofAdministration 2019-2030 (By Value)
11.3.1.3. Global Novel Vaccine Delivery Device Market: Distribution by Type ofVaccine 2019-2030 (By Value)
11.3.1.4. Global Novel Vaccine Delivery Device Market: Distribution by Regions,2019-2030 (By Value)
11.3.1.4.1. Novel Vaccine Delivery Devices Market in North America, 2019-2030(By Value)
11.3.1.4.1.1. Novel Vaccine Delivery Devices Market in North America:Distribution by Type of Device, 2019-2030 (By Value)
11.3.1.4.1.2. Novel Vaccine Delivery Devices Market in North America: Distributionby Route of Administration, 2019-2030 (By Value)
11.3.1.4.1.3. Novel Vaccine Delivery Devices Market in North America:Distribution by Type of Vaccine, 2019-2030 (By Value)
11.3.1.4.2. Novel Vaccine Delivery Devices Market in Europe,2019-2030 (By Value)
11.3.1.4.2.1. Novel Vaccine Delivery Devices Market in Europe: Distribution byType of Device, 2019-2030 (By Value)
11.3.1.4.2.2. Novel Vaccine Delivery Devices Market in Europe: Distribution byRoute of Administration, 2019-2030 (By Value)
11.3.1.4.2.3. Novel Vaccine Delivery Devices Market in Europe: Distribution byType of Vaccine, 2019-2030 (By Value)
11.3.1.4.3. Novel Vaccine Delivery Devices Market in AsiaPacific, 2019-2030 (By Value)
11.3.1.4.3.1. Novel Vaccine Delivery Devices Market in Asia Pacific:Distribution by Type of Device, 2019-2030 (By Value)
11.3.1.4.3.2. Novel Vaccine Delivery Devices Market in Asia Pacific:Distribution by Route of Administration, 2019-2030 (By Value)
11.3.1.4.3.3. Novel Vaccine Delivery Devices Market in Asia Pacific:Distribution by Type of Vaccine, 2019-2030 (By Value)
11.3.1.4.4. Novel Vaccine Delivery Devices Market in Rest of theWorld, 2019-2030 (By Value)
11.3.1.4.4.1. Novel Vaccine Delivery Devices Market in Rest of the World:Distribution by Type of Device, 2019-2030 (By Value)
11.3.1.4.4.2. Novel Vaccine Delivery Devices Market in Rest of the World:Distribution by Route of Administration, 2019-2030 (By Value)
11.3.1.4.4.3. Novel Vaccine Delivery Devices Market in Rest of the World:Distribution by Type of Vaccine, 2019-2030 (By Value)
11.3.2. Global NovelVaccine Delivery Device Market, 2019-2030 (By Volume)
11.3.2.1. Global Novel Vaccine Delivery Device Market: Distribution by Type ofDevice, 2019-2030 (By Volume)
11.3.2.2. Global Novel Vaccine Delivery Device Market: Distribution by Route ofAdministration, 2019-2030 (By Volume)
11.3.2.3. Global Novel Vaccine Delivery Device Market: Distribution by Type ofVaccine, 2019-2030 (By Volume)
11.3.2.4. Global Novel Vaccine Delivery Device Market: Distribution by Regions,2019-2030 (By Volume)
11.3.2.4.1. Novel Vaccine Delivery Device Market in NorthAmerica, 2019-2030 (By Volume)
11.3.2.4.1.1. Novel Vaccine Delivery Devices Market in North America:Distribution by Type of Device, 2019-2030 (By Volume)
11.3.2.4.1.2. Novel Vaccine Delivery Devices Market in North America:Distribution by Route of Administration, 2019-2030 (By Volume)
11.3.2.4.1.3. Novel Vaccine Delivery Devices Market in North America:Distribution by Type of Vaccine, 2019-2030 (By Volume)
11.3.2.4.2. Novel Vaccine Delivery Devices Market in Europe,2019-2030 (By Volume)
11.3.2.4.2.1. Novel Vaccine Delivery Devices Market in Europe: Distribution byType of Device, 2019-2030 (By Volume)
11.3.2.4.2.2. Novel Vaccine Delivery Devices Market in Europe: Distribution byRoute of Administration, 2019-2030 (By Volume)
11.3.2.4.2.3. Novel Vaccine Delivery Devices Market in Europe: Distribution byType of Vaccine, 2019-2030 (By Volume)
11.3.2.4.3. Novel Vaccine Delivery Devices Market in AsiaPacific, 2019-2030 (By Volume)
11.3.2.4.3.1. Novel Vaccine Delivery Devices Market in Asia Pacific:Distribution by Type of Device, 2019-2030 (By Volume)
11.3.2.4.3.2. Novel Vaccine Delivery Devices Market in Asia Pacific:Distribution by Route of Administration, 2019-2030 (By Volume)
11.3.2.4.3.3. Novel Vaccine Delivery Devices Market in Asia Pacific:Distribution by Type of Vaccine, 2019-2030 (By Volume)
11.3.2.4.4. Novel Vaccine Delivery Devices Market in Rest of theWorld, 2019-2030 (By Volume)
11.3.2.4.4.1. Novel Vaccine Delivery Devices Market in Rest of the World:Distribution by Type of Device, 2019-2030 (By Volume)
11.3.2.4.4.2. Novel Vaccine Delivery Devices Market in Rest of the World:Distribution by Route of Administration, 2019-2030 (By Volume)
11.3.2.4.4.3. Novel Vaccine Delivery Devices Market in Rest of the World:Distribution by Type of Vaccine, 2019-2030 (By Volume)
12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. Vaxess Technologies
12.2.1. Company Snapshot
12.2.1.1. Interview Transcript: Michael Schrader, Chief Executive Officer andFounder
12.3. Iconovo
12.3.1. Company Snapshot
12.3.1.1. Interview Transcript: Mikael Ekstrom and Roger Lassing, VicePresidents, Business Development
12.4. Innoture
12.4.1. Company Snapshot
12.4.1.1. Interview Transcript: Henry King, Market Intelligence and DevelopmentManager
13. CONCLUDINGREMARKS
13.1. Chapter Overview
13.2. Key Takeaways
14. APPENDIXI: TABULATED DATA
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
